Macquarie Group’s Third Harmonic Bio THRD Stock Holding History

Macquarie Group’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,040	Closed	-$42	–	1799
2024 Q4	$42	Buy	+4,040	New	+$50.3K	﹤0.01%	1647

Other funds holding THRD

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Macquarie Group's THRD Position: Q1 2025 in Review

Macquarie Group sold out of Third Harmonic Bio (THRD) in Q1 2025, closing a stake of 4,040 shares — an estimated $42 sold.

Macquarie Group first reported a position in THRD in Q4 2024 and held it in 1 quarter. The position peaked at $42 in Q4 2024. 99 funds tracked by Wall St. Rank hold THRD as of Q1 2025.

Macquarie Group reported no remaining Third Harmonic Bio position as of Q1 2025 after selling out during the quarter.
Macquarie Group sold 4,040 Third Harmonic Bio shares in Q1 2025, an estimated $42.
Macquarie Group first reported a position in Third Harmonic Bio in Q4 2024 and held it in 1 quarter.
Macquarie Group's Third Harmonic Bio position peaked at $42 in Q4 2024.
99 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2025.

Based on Macquarie Group's 13F filing for Q1 2025, filed 15 May 2025.